Compare Invesco S&P 500 Momentum ETF (SPMO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs Stryker Corporation — how do they compare? Invesco S&P 500 Momentum ETF trades at $152 (market cap $23.48B), while Stryker Corporation trades at $276.85 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4.5× Invesco S&P 500 Momentum ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Momentum ETF for 54 Days and Stryker Corporation for 20 Days on average.
| SPMO | SYK | |
|---|---|---|
Market Cap | $23.48B | $106.24B |
Volume | 1,876,152 | 2,982,001 |
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $388.35 |
52-Week Low | $107.84 | $269.75 |
Typical Hold Time | 54 Days | 20 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO trades at $153.00 with minimal daily movement (+0.01%). The ETF maintains a bullish technical stance with strong moving average signals, though oscillators show neutral momentum. Recent portfolio rebalancing added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest grew with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
SPMO offers concentrated exposure to S&P 500 momentum leaders with historical outperformance. Key risks include sector concentration in technology and semiconductors, plus higher volatility than the broader market. The fund's momentum strategy faces challenges during market rotations but maintains structural advantages for long-term growth investors.
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
